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Aberrant ERBB receptor activity contributes to the development of many human cancers. Receptor overexpression, kinase 
domain (KD) mutations, and autocrine ligand production contribute to ERBB activation in human tumors. ERBB-targeted tyrosine 
kinase inhibitors (TKIs) and monoclonal antibodies are used in cancer treatment; however, clinical hurdles, including patient 
selection and TKI resistance, need to be overcome in order to optimize therapy. This minireview will discuss recent findings on 
possible mechanisms leading to ERBB-targeted therapy resistance and potential means to overcome them.The ERBB receptor-ligand network comprises four receptors, 
EGFR, ERBB2, ERBB3, and ERBB4; and multiple ligands, the 
EGF-related peptides (Yarden and Sliwkowski, 2001). ERBB recep-
tors are activated in response to peptide binding, leading to ERBB 
receptor homo- and heterodimerization (Holbro and Hynes, 2004). 
There are three ligand groups: EGF, TGF-α, amphiregulin, and epi-
gen, which bind EGFR; BTC, HB-EGF, and epiregulin, which bind 
EGFR or ERBB4; and neuregulins (NRGs, also known as heregu-
lins [HRG]), which bind ERB3 and ERBB4. Despite the fact that 
none of the EGF-related peptides binds ERBB2, this receptor is the 
preferred dimerization partner for the other ligand-activated ERBBs 
(Graus-Porta et al., 1997). Aberrant EGFR and ERBB2 activ-
ity contributes to human cancer. Numerous clinical studies have 
implicated these receptors in the pathology of specific tumor types 
(Nicholson et al., 2001; Ross et al., 2003). The three major mecha-
nisms leading to ERBB activation in cancer are gene amplification, 
altered ligand expression, and mutations in the receptor kinase or 
extracellular domain (Hynes and Lane, 2005). Intense efforts have 
gone into developing ERBB-targeted inhibitors, focusing either 
on the extracellular domain with antibody-based approaches or 
on blockade of the intracellular kinase domain (KD) with tyrosine 
kinase inhibitors (TKIs) (Baselga and Arteaga, 2005; Blackhall et 
al., 2006; Hynes and Lane, 2005). A mechanistic understanding 
of how these inhibitors impact on tumor cells will be essential to 
further enhance the current clinical successes (see, for example, 
Piccart-Gebhart et al., 2005). Furthermore, in order to improve 
patient selection optimization of factors that predict response or 
resistance to a specific therapeutic must continue. Two papers in 
this issue of Cancer Cell shed more light on these problems (Wang 
et al., 2006; Zhou et al., 2006). We will briefly present some back-
ground before discussing these papers.
The first large-scale clinical trials using EGFR TKIs were car-
ried out in non-small cell lung cancer (NSCLC) patients. The over-
all response rate to the inhibitors was low (reviewed in Blackhall et 
al., 2006). However, the first somatic mutations in the KD of EGFR 
were discovered in tumors from those patients who were sensitive 
to the EGFR-selective TKIs gefitinib and erlotinib; >80% (n = 31) 
of the responders had KD mutations (Lynch et al., 2004; Paez et 
al., 2004; Pao et al., 2004). Although to a lower extent, KD muta-
tions in ERBB2 have also been detected in NSCLC (Figure 1 and 
Table 1) (Stephens et al., 2004; Shigematsu et al., 2005; Takano 
et al., 2005; Lee et al., 2006a; Sasaki et al., 2006). Needless to 
say, the pattern of response to ERBB-targeted TKIs and EGFR 
mutation status have been closely monitored during the past few 
years. Newer studies reported response rates for NSCLC patients 
with EGFR KD mutations ranging from 16% (Tsao et al., 2005) to 
cancer cell 10, July 2006 ©2006 ElsEviEr inc. 65% (Johnson and Janne, 2005). These wide differences might 
reflect diverse patient populations. The expression level of EGFR 
has also been associated with gefitinib and erlotinib response 
(Cappuzzo et al., 2005a; Takano et al., 2005; Tsao et al., 2005; 
Shepherd et al., 2005). However, objective responses to TKIs 
have also been observed in the absence of EGFR KD mutations 
or overexpression (Pao et al., 2004; Tsao et al., 2005; Takano et 
al., 2005), suggesting that other factors also contribute to TKI 
sensitivity. These clinical studies have led to intense efforts, first 
to clarify if ERBB KD mutations and/or additional factors predict 
TKI response, and second, to characterize the role of mutant 
ERBBs in cancer biology.
Figure 1. Kinase domain mutations in ErBB receptors
structure of a full-length ErBB with the indicated domains: ligand binding (lB 
i and ii), transmembrane (TM), kinase (KD), and cytoplasmic tail (cT). The KDs 
of EGFr, ErBB2, and ErBB4 are shown enlarged, with the elucidated structure 
of the EGFr KD consisting of the n-terminal lobe with the ATP binding site 
(yellow) and the c-terminal lobe (green) containing the activation loop 
(orange). Alterations in EGFr labeled in blue are associated with increased 
transforming activity and increased sensitivity to the TKis gefitinib and erlo-
tinib; T90M (red) confers resistance to both. Mutations, deletions, and inser-
tions in ErBB2 are also clustered in the n lobe of the receptor. The G6yvMA 
and vc insertions enhance ErBB2 activity (Wang et al., 2006). One mutation 
(*) was reported in a gefitinib-responsive sccHn patient in the absence of 
EGFr mutation (cohen et al., 2005). ErBB4 mutations are found in a variety of 
cancers (soung et al., 2006). del, deletion; ins, insertion; dup, duplication.
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cancer Frequency remarks reference
nsclc 5/120 (4.2%), 5/51 (9.8%) adenocarcinoma, insertions in exon 20 (4/5), l55P in exon 19 stephens et al., 2004
11/61 (1.6%), 11/394 (2.8%) adenocarcinoma, in-frame duplications/insertions in exon 20 shigematsu et al., 2005
1/80 (1.3%) tumor cell lines, (+) from adenocarcinoma, in-frame duplications/insertions in exon 20
0/66 gefitinib-treated patients Takano et al., 2005
1/114 (0.8%) nonadenocarcinoma, G6ins yvMA exon 20 lee et al., 2006a
1/122 (0.8%) adenocarcinoma, G6ins yvMA sasaki et al., 2006
Total 18/1093 (1.6%) 1 adenocarcinomas
sclc 0/36 shigematsu et al., 2005
Gastric 9/180 (5%) various mutations lee et al., 2006b
crc 0/28 shigematsu et al., 2005
3/104 (2.9%) all carry K-ras mutations, vl, M; v842i lee et al., 2006b
Total 3/132 (2.3%)
Breast 0/28 shigematsu et al., 2005
4/94 (4.3%) none with ErbB2 amplification, del l55-T59, l55s, P; r896c lee et al., 2006b
Total 4/122 (3.3%)
sccHn 1/4 (25%) Gefitinib-responsive patient, v3A cohen et al., 2005
Bladder 0/15 shigematsu et al., 2005
Prostate 0/14 shigematsu et al., 2005
Ovary 1/188 (0.5%) G6ins yvMA exon 20 lassus et al., 2006The biochemical and biological consequences of EGFR muta-
tions have been studied by various means. Most of the missense 
mutations and in-frame deletions that arise in exons 18–21 of the 
KD affect residues in the ATP binding pocket (Figure 1). Recent 
mutational and crystallographic studies revealed that the kinase 
activity of EGFRWT is autoinhibited and that this conformation is 
destabilized by a common mutation, L834R, conferring on the 
mutant a dramatic increase in basal and ligand-induced kinase 
activity (Zhang et al., 2006). In vitro data from cellular models 
suggest that KD mutations enhance coupling of the mutant recep-
tor to prosurvival pathways (Greulich et al., 2005; Sordella et al., 
2004). This hypothesis is supported by the clinical observation 
that increased EGFR copy number was observed more frequently 
in patients bearing EGFR KD mutations than in patients with 
EGFRWT (Cappuzzo et al., 2005a), suggesting that mutant EGFR 
alleles are selectively amplified and required for NSCLC survival. 
Results from transgenic models provide convincing support for the 
importance of EGFR KD mutations in lung cancer (Ji et al., 2006; 
Politi et al., 2006). Inducible expression of two common EGFR 
mutations in transgenic animals rapidly induced lung adenocar-
cinomas with features similar to those seen in human tumors 
with EGFR KD mutations. Withdrawal of the inducer led to tumor 
regression in the mice, demonstrating the importance of mutant 
EGFR in cancer cell survival. Importantly, the mice responded to 
EGFR-selective TKIs, rapidly demonstrating a significant tumor 
reduction (Ji et al., 2006). These mice provide excellent models 
for further studies on tumor biology and response.
ERBB2 KD mutations were initially detected in NSCLC 
(Stephens et al., 2004), although at a lower frequency than EGFR 
mutations. However, neither the biology of mutant ERBB2 nor its 
impact on clinical response to TKIs has been reported. This is 
where the new study of Arteaga and colleagues comes into the pic-
ture (Wang et al., 2006). The group examined the biological effects 
of two different ERBB2 KD mutants, the G776YVMA and G776VC 8 insertions. Following introduction into normal human breast and 
lung cells, mutant ERBB2 was constitutively active and conferred 
oncogenic properties on the cells. Moreover, EGFR displayed 
elevated activity, and multiple downstream signaling pathways 
were stimulated. Mutant ERBB2-expressing cells were tested for 
their sensitivity to various ERBB inhibitors. Although these cells 
were resistant to the EGFR-selective TKIs gefitinib and erlotinib, 
they were sensitive to the dual EGFR/ERBB2 TKIs lapatinib and 
CI-1033, showing the dominance of mutant ERBB2 in this model. 
In the clinic it is not yet known if ERBB2 KD mutations confer 
resistance to gefitinib or erlotinib in NSCLC patients. In one small 
study that included four patients with ERBB2 KD mutation, none 
responded to gefitinib (Han et al., 2006), supporting the in vitro 
results presented by Arteaga and colleagues. In addition to their 
sensitivity to the dual ERBB TKIs, the transformed cells were also 
sensitive to the ERBB2-targeted monoclonal antibody trastuzumab 
(Wang et al., 2006). It is well documented that breast cancers with 
ERBB2 amplification respond to trastuzumab (Hynes and Lane, 
2005), and data are emerging that elevated ERBB2 copy number 
might impact on response of NSCLC patients to ERBB-targeted 
therapies (Cappuzzo et al., 2005c). ERBB2 amplification is found in 
11% of NSCLC specimens (discussed in Rosell, 2004), and results 
from clinical trials suggest that the subgroup of patients with ampli-
fication achieve clinical benefit when trastuzumab is added to differ-
ent chemotherapy regimes (Langer et al., 2004). Intriguingly, it was 
recently reported that trastuzumab in combination with paclitaxel 
led to a partial response of a NSCLC patient with increased ERBB2 
copy number and an ERBB2 KD mutation (G776L) (Cappuzzo et 
al., 2006). Although currently based on one example, it is pos-
sible that screening for ERBB2 amplification in combination with 
mutation will be the ultimate test for choosing NSCLC patients 
who might be considered for trastuzumab therapy. Based upon the 
results reported by Wang et al. (2006), these patients might also 
respond to a dual EGFR/ERBB2 inhibitor.cancer cell July 2006
	 m i n i r e v i e wTable 2. ADAMs, ErBB ligand shedding, and potential roles in different cancer types
ADAM shedding of ErBB ligands Expression in cancer reference
ADAM8 ? rcc, nsclc, brain rocks et al., 2006
ADAM9 HB-EGF myeloma, breast, gastric, prostate, nsclc, melanoma, Hcc sahin et al., 2004
ADAM10 HB-EGF, EGF, BTc breast, crc, uterus, ovary, prostate, hematological malignancies, gastric sahin et al., 2004
ADAM12 HB-EGF breast, gastric, glioblastoma, hematological malignancies, liver, colon Asakura et al., 2002
ADAM15 HB-EGF, Ar, TGFα breast, hematological malignancies, gastric, prostate, lung carcinoma Hart et al., 2005
ADAM1 HB-EGF, Ar, TGFα, EPr, nrGα2c, -β1, -β2 breast, prostate, gastric, crc, Hcc, ovary, rcc Horiuchi et al., 2005
ADAM19 nrGβ1, -4 brain, rcc Wildeboer et al., 2006
ADAM28 ? nsclc Ohtsuka et al., 2006There is emerging evidence that ERBB3 and ERBB4 also 
have roles in common human cancers. ERBB4 KD mutations 
have been detected in 2.0% of tumor tissues (n = 594), includ-
ing 2.3% of NSCLCs (n = 217) (Soung et al., 2006). Neither 
their impact on response to ERBB TKIs nor their biology has 
been studied. Genomic gain of ERBB3 does not appear to be a 
marker for response to TKI therapy in NSCLC (Cappuzzo et al., 
2005b), which is not surprising since this kinase-impaired recep-
tor acquires signaling activity only as a heterodimer with another 
ERBB (Hynes and Lane, 2005). However, there are data suggest-
ing that lung cancers that depend upon EGFR for survival activate 
ERBB3 via upregulation of EGF-related peptides (Fujimoto et al., 
2005). Although ERBB3 is kinase impaired, its ability to strongly 
couple to PI3K confers a special role on this receptor. Cancer 
cells driven by ERBB2 (Holbro et al., 2003) or EGFR (Engelman 
et al., 2005) coopt ERBB3 to activate the PI3K/AKT pathway. In 
summary, an assessment of ERBB3 levels combined with ERBB2 
copy number and/or mutation status in NSCLC may also prove 
useful for predicting response to ERBB-targeted TKIs.
Resistance to ERBB inhibitors, both TKIs and antibodies, has 
emerged as a significant clinical problem. Resistance may be de 
novo, for example, in those NSCLC patients with EGFR KD muta-
tions who never responded to TKIs. Or it is acquired, as seen in 
some cases where tumors arising during gefitinib or erlotinib ther-
apy contained a secondary mutation, T790M (Kobayashi et al., 
2005; Pao et al., 2005). Based upon the model of erlotinib bound 
to the KD of EGFR, the change at residue 790 is predicted to keep 
the receptor active but prevent the TKI from binding (Kobayashi 
et al., 2005). Fortunately, this class of TKI-resistant mutants is 
sensitive to other EGFR inhibitors, such as CL-387,785 (Greulich 
et al., 2005).
Acquired resistance also results from alterations in EGFR 
trafficking (Kwak et al., 2005), a process that is subject to mul-
tiple control mechanisms (Lenferink et al., 1998) and plays an 
important role in receptor signaling activity (Wiley, 2003). In a 
NSCLC cell line model of acquired gefitinib resistance, EGFR 
internalization was more rapid in the resistant than in the parental 
cells (Kwak et al., 2005). Importantly, the gefitinib-resistant cells 
remained sensitive to irreversible ERBB-selective TKIs (Kwak et 
al., 2005). These results suggest that intracellular dissociation of 
reversible ERBB inhibitors may play a role in resistance and that 
an irreversible TKI might not be subject to this effect. In fact, dif-
ferences in EGFR trafficking in cancer cells might have a general 
role in TKI response, and it will be interesting to develop additional 
in vitro models for testing this.
The paper by Zhou and colleagues presents evidence for 
another resistance mechanism in NSCLC, one that involves cancer cell July 2006 autocrine ligand production (Zhou et al., 2006). The EGF-related 
peptides are synthesized as transmembrane precursors that are 
cleaved by cell surface proteases (Harris et al., 2003), leading 
to the release of soluble ligands. This cleavage is an important 
step in the control of ligand availability and receptor activation 
(Borrell-Pages et al., 2003). The ADAMs (a disintegrin and metal-
loproteases), zinc-dependent membrane-associated proteases, 
control the cleavage of most EGF-related ligands (Blobel, 2005). 
The ADAMs family has 29 mammalian members that share a 
common molecular structure. Catalytically active ADAMs cleave 
a variety of substrates, including growth factors and extracellular 
matrix proteins (Blobel, 2005; Seals and Courtneidge, 2003; Zhou 
et al., 2005). Various lines of evidence suggest that ADAM10 and 
ADAM17 are the principle proteases for the ERBB ligands (Sahin 
et al., 2004).
Zhou and colleagues provide evidence suggesting that HRG-
mediated ERBB3 activation might be an important gefitinib resis-
tance mechanism. An examination of primary NSCLC tissues 
revealed that most expressed HRG and ERBB3; active ERBB3 
was found in a subset. Since NSCLCs also express EGFR and 
ERBB2, they hypothesized that autocrine HRG activation of 
ERBB3-containing heterodimers might prevent gefitinib response, 
since these heterodimers are unlikely to respond to the EGFR-
selective TKI. This was tested using NSCLC cell lines, where they 
showed that gefitinib insensitivity significantly correlated with HRG 
expression. Based upon ADAM17 overexpression in tumors with 
ERBB3 activity, and the role of ADAM10 and ADAM17 in ERBB 
ligand cleavage, they identified INCB3619, a small molecule that 
strongly inhibits both ADAMs. Importantly, this dual ADAM inhibi-
tor blocked HRG release in a gefitinib-resistant NSCLC cell line, 
sensitizing the tumor cells to the TKI.
These are exciting results, since ADAM10 has also been 
implicated in autocrine EGFR activity in breast cancer (Borrell-
Pages et al., 2003; see Table 2 for other ADAMs implicated in 
cancer). Furthermore, in ERBB2-positive breast cancer, auto-
crine ligand production might also interfere with trastuzumab 
response, since trastuzumab-sensitive breast tumor cell lines 
become resistant to the antibody in the presence of EGF-related 
ligands (Motoyama et al., 2002). Trastuzumab binds domain IV of 
ERBB2, a region not involved in receptor dimerization (Cho et al., 
2003), which explains why ERBB ligands can induce activation of 
ERBB2-containing dimers in the presence of the antibody. At this 
point one might ask whether a dual EGFR/ERBB2 inhibitor that 
should also block HRG-induced ERBB2/ERBB3 heterodimers 
might be sufficient to overcome HRG-mediated resistance, mak-
ing combined inhibition of ERBBs and ADAMs superfluous. Since 
Zhou and colleagues only examined sensitivity of NSCLC cell 9
	 m i n i r e v i e wlines to gefitinib, these data are not available. However, it should 
be kept in mind that ADAMs have many substrates whose pro-
cessing might circumvent ERBB inhibition by other mechanisms. 
In fact, ADAMs cleave the ectodomain of ERBB2, leaving behind 
an active truncated receptor (Molina et al., 2001). Furthermore, 
ADAM-mediated proteolysis of IGFBPs (discussed in Zhou et al., 
2005) releases IGF-1, a peptide known to play a role in circum-
venting ERBB inhibitors (Lu et al., 2001). In summary, information 
from the new papers in this issue of Cancer Cell suggest that dual 
EGFR/ERBB2 inhibitors either alone or combined with a selective 
ADAM inhibitor might be effective in cancers with autocrine ligand 
activation of ERBB receptors and ERBB KD mutations.
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